Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation.
Fangzhou LiXufeng PengJiale ZhouQi ChenYonghui ChenPublished in: Journal of cancer research and clinical oncology (2022)
MEK5 expression was aberrantly increased in ccRCC, which activated the mTOR signalling pathway and regulated cell proliferation, cell cycle progression, migration, and clone formation in ccRCC. Targeted inhibition of MEK5 represents a promising new strategy in patients with ccRCC.